Definium Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Definium Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $56. The average 1-year stock price forecast is 23.95% higher than the current stock price, while the lowest is $30 (-33.60%) and the highest is $74 (+63.79%).

Price Target: $56 (+23.95%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$30	$56	$57	$74
Change	-33.60%	+23.95%	+26.16%	+63.79%

Analyst Ratings

The average analyst rating for Definium Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	11	12	11	12	12	11
Buy	3	3	3	4	4	4
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	14	15	14	16	16	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Okunewitch Maxim Group	Maxim Group	Buy Reiterates $40 → $50	Buy	Reiterates	$40 → $50	+10.67%	Jun 23, 2026
Justin Walsh JonesTrading	JonesTrading	Buy Reiterates $61 → $74	Buy	Reiterates	$61 → $74	+63.79%	Jun 23, 2026
Christopher Chen Robert W. Baird	Robert W. Baird	Buy Maintains $37 → $57	Buy	Maintains	$37 → $57	+26.16%	Jun 23, 2026
Sumant Kulkarni Canaccord Genuity	Canaccord Genuity	Buy Maintains $38 → $60	Buy	Maintains	$38 → $60	+32.80%	Jun 22, 2026
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $70	Buy	Reiterates	$70	+54.94%	Jun 22, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

27.33M

EPS This Year

-2.30

from -2.06

EPS Next Year

-1.59

from -2.30

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-93.55M	-66.33M	-93.87M	-103.92M	-166.31M	-238.63M
Net Income	-93.04M	-56.80M	-95.73M	-108.68M	-183.79M	-254.56M
EPS	-	-	-	-	-2.06	-2.30
Free Cash Flow	-8.21M	-15.82M	-26.39M	-45.28M	-57.81M	-203.64M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-1.85
Avg	-2.30
Low	-2.67

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-